<!doctype html>
<html lang="it">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Rassegna Ponatinib / Asciminib CML</title>
  <style>
    body {
      font-family: Arial, sans-serif;
      line-height: 1.5;
      margin: 24px auto;
      max-width: 900px;
      padding: 0 16px;
      color: #222;
      background: #fff;
    }
    h1, h2, h3 { line-height: 1.2; }
    h1 { border-bottom: 2px solid #ddd; padding-bottom: 8px; }
    h2 { margin-top: 28px; border-bottom: 1px solid #eee; padding-bottom: 4px; }
    h3 { margin-top: 22px; }
    ul { margin-top: 6px; margin-bottom: 10px; }
    li { margin-bottom: 6px; }
    hr { margin: 22px 0; border: none; border-top: 1px solid #ddd; }
    a { color: #0b57d0; text-decoration: none; }
    a:hover { text-decoration: underline; }
    p { margin: 8px 0; }
  </style>
</head>
<body>
<h1>Ponatinib / Asciminib nella LMC – Report strategico quindicinale (ultimi 30 giorni)</h1>
<p>_Generata il: 2026-02-23_</p>
<p></p>
<h2>Executive brief</h2>
<p></p>
<p><b>3 takeaway (cosa conta davvero):</b></p>
<ul>
<li>Nel periodo emergono soprattutto temi su <b>Resistenza / T315I / mutazioni</b> (n=3).</li>
<li>Secondo filone: <b>Safety e comorbidità</b> (n=3).</li>
<li>Terzo filone: <b>Dose strategy / consolidamento</b> (n=2).</li>
</ul>
<p></p>
<p><b>Watchlist (cosa tenere d’occhio):</b></p>
<ul>
<li>Monitorare evoluzione su <b>Safety e comorbidità</b> (nuovi segnali/dati).</li>
<li>Monitorare evoluzione su <b>Resistenza / T315I / mutazioni</b> (nuovi segnali/dati).</li>
</ul>
<p></p>
<p><b>Action list (cosa fare in pratica):</b></p>
<ul>
<li>Rivedere/rafforzare <b>monitoraggio cardiovascolare e interazioni</b> (es. anticoagulanti) nei pazienti in TKI.</li>
<li>Valutare criteri interni per <b>consolidamento / de-escalation / TFR</b> nei pazienti in deep response.</li>
<li>Verificare percorso di <b>test mutazionale</b> e criteri di switch nelle resistenze (incl. T315I).</li>
</ul>
<p></p>
<hr>
<p></p>
<h2>Top 5 da leggere subito (ordinati per impatto)</h2>
<p></p>
<h3>1) Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?</h3>
<ul>
<li><b>Impact score</b>: 12 | <b>Tipo</b>: Trial clinico</li>
<li><b>Focus clinico</b>: Resistenza / T315I / mutazioni, Safety e comorbidità</li>
<li>PMID: 41724089 | 10.1016/j.htct.2026.106257</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41724089/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41724089/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.</li>
<li>Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.</li>
<li>Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>2) Advances in Targeting BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt; Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.</h3>
<ul>
<li><b>Impact score</b>: 12 | <b>Tipo</b>: Review</li>
<li><b>Focus clinico</b>: Resistenza / T315I / mutazioni, Dose strategy / consolidamento, Safety e comorbidità, Sintesi (review/linee guida)</li>
<li>PMID: 41599389 | 10.3390/molecules31020341</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41599389/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41599389/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to imatinib remains a therapeutic challenge, largely driven by point mutations within the kinase domain of the &lt;i&gt;BCR-ABL&lt;/i&gt;, among which the &lt;i&gt;T315I&lt;/i&gt; substitution constitutes the most clinically significant barrier.</li>
<li>Risultato chiave: Recent advances highlight aminopyrimidine-derived scaffolds and their evolution into thienopyrimidines, oxadiazoles, and pyrazines with improved activity against &lt;i&gt;BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt;&lt;/i&gt;.</li>
<li>Rilevanza clinica: Hybrid molecules derived from approved &lt;i&gt;TKIs&lt;/i&gt;, including GNF-7, olverembatinib, and HG-7-85-01, exemplify rational design trends that balance efficacy with improved safety.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>3) Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries.</h3>
<ul>
<li><b>Impact score</b>: 7 | <b>Tipo</b>: Farmacovigilanza</li>
<li><b>Focus clinico</b>: Safety e comorbidità</li>
<li>PMID: 41598268 | 10.3390/life16010113</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41598268/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41598268/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: The tyrosine kinase inhibitors (TKIs) asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib have been approved for chronic myelogenous leukemia (CML) therapy.</li>
<li>Risultato chiave: To better clarify TKIs&#x27; pulmonary risk, we used the European database EudraVigilance to conduct a study on adverse events suspected to be caused by the TKIs asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib when used for CML therapy.</li>
<li>Rilevanza clinica: The results indicate that respiratory disorders induced by the TKIs dasatinib and bosutinib need to be diagnosed in a timely manner, and suggest that caution should be taken when prescribing these TKIs to patients affected by CML and pulmonary comorbidities.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>4) Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.</h3>
<ul>
<li><b>Impact score</b>: 5 | <b>Tipo</b>: Preclinico / laboratorio</li>
<li><b>Focus clinico</b>: Resistenza / T315I / mutazioni, Dose strategy / consolidamento</li>
<li>PMID: 41696976 | 10.1111/jcmm.71053</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41696976/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41696976/</a></li>
</ul>
<p></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.</li>
<li>Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.</li>
<li>Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.</li>
</ul>
<p></p>
<hr>
<p></p>
<h2>Evidenze per domande cliniche</h2>
<p></p>
<h3>Resistenza / T315I / mutazioni (3)</h3>
<p></p>
<p>#### Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?</p>
<ul>
<li>Impact score: 12 | Tipo: Trial clinico</li>
<li>PMID: 41724089 | 10.1016/j.htct.2026.106257</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41724089/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41724089/</a></li>
<li>Open Access (Europe PMC/PMC): non rilevato</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.</li>
<li>Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.</li>
<li>Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Advances in Targeting BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt; Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.</p>
<ul>
<li>Impact score: 12 | Tipo: Review</li>
<li>PMID: 41599389 | 10.3390/molecules31020341</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41599389/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41599389/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12843680)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to imatinib remains a therapeutic challenge, largely driven by point mutations within the kinase domain of the &lt;i&gt;BCR-ABL&lt;/i&gt;, among which the &lt;i&gt;T315I&lt;/i&gt; substitution constitutes the most clinically significant barrier.</li>
<li>Risultato chiave: Recent advances highlight aminopyrimidine-derived scaffolds and their evolution into thienopyrimidines, oxadiazoles, and pyrazines with improved activity against &lt;i&gt;BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt;&lt;/i&gt;.</li>
<li>Rilevanza clinica: Hybrid molecules derived from approved &lt;i&gt;TKIs&lt;/i&gt;, including GNF-7, olverembatinib, and HG-7-85-01, exemplify rational design trends that balance efficacy with improved safety.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): In this review, we summarized the diverse medicinal chemistry strategies currently being pursued to overcome the BCR-ABLT315I gatekeeper mutation, one of the most challenging resistance mechanisms in chronic myeloid leukemia therapy.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.</p>
<ul>
<li>Impact score: 5 | Tipo: Preclinico / laboratorio</li>
<li>PMID: 41696976 | 10.1111/jcmm.71053</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41696976/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41696976/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12908417)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.</li>
<li>Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.</li>
<li>Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): For single‐agent dose–response experiments, cells were treated with 10‐fold serial dilutions ranging from 0 to 1 μM for asciminib and ponatinib and from 0 to 100 nM for bortezomib and panobinostat.</li>
<li>Risultato principale (full text OA): Asciminib is a STAMP inhibitor approved for CML [18].</li>
<li>Dettaglio utile (full text OA): (A) CML cell lines (K562, K562 PR, K562 IR, Ba/F3 asc‐R, Ba/F3 PR, Ba/F3 BCR::ABL, and Ba/F3 T315I) were exposed to asciminib (0–1 μM) for 72 h, and cell viability was measured using the Cell Counting Kit‐8 (CCK‐8) assay.</li>
<li>Messaggio clinico (full text OA): A prior clinical trial explored the combination of a proteasome inhibitor with an HDAC inhibitor in a phase I dose‐escalation study involving belinostat and bortezomib in adult patients with acute leukaemia, myelodysplastic syndromes, or blast‐crisis CML [27].</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>Safety e comorbidità (3)</h3>
<p></p>
<p>#### Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?</p>
<ul>
<li>Impact score: 12 | Tipo: Trial clinico</li>
<li>PMID: 41724089 | 10.1016/j.htct.2026.106257</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41724089/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41724089/</a></li>
<li>Open Access (Europe PMC/PMC): non rilevato</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Such a selective inhibitor offers an alternative treatment strategy for patients with chronic myeloid leukemia who have developed resistance to previous tyrosine kinase inhibitor therapies.</li>
<li>Risultato chiave: Although asciminib demonstrates a superior safety profile, primarily characterized by a reduction in cardiovascular adverse events associated with prior tyrosine kinase inhibitors, its clinical significance extends further.</li>
<li>Rilevanza clinica: It remains essential to continue research and clinical trials to enhance the therapeutic efficacy of asciminib and manage its associated side effects.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Advances in Targeting BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt; Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.</p>
<ul>
<li>Impact score: 12 | Tipo: Review</li>
<li>PMID: 41599389 | 10.3390/molecules31020341</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41599389/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41599389/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12843680)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to imatinib remains a therapeutic challenge, largely driven by point mutations within the kinase domain of the &lt;i&gt;BCR-ABL&lt;/i&gt;, among which the &lt;i&gt;T315I&lt;/i&gt; substitution constitutes the most clinically significant barrier.</li>
<li>Risultato chiave: Recent advances highlight aminopyrimidine-derived scaffolds and their evolution into thienopyrimidines, oxadiazoles, and pyrazines with improved activity against &lt;i&gt;BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt;&lt;/i&gt;.</li>
<li>Rilevanza clinica: Hybrid molecules derived from approved &lt;i&gt;TKIs&lt;/i&gt;, including GNF-7, olverembatinib, and HG-7-85-01, exemplify rational design trends that balance efficacy with improved safety.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): In this review, we summarized the diverse medicinal chemistry strategies currently being pursued to overcome the BCR-ABLT315I gatekeeper mutation, one of the most challenging resistance mechanisms in chronic myeloid leukemia therapy.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Adverse Respiratory Reactions to Tyrosine Kinase Inhibitors: A Disproportionality Analysis of Spontaneous Reports from European Countries.</p>
<ul>
<li>Impact score: 7 | Tipo: Farmacovigilanza</li>
<li>PMID: 41598268 | 10.3390/life16010113</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41598268/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41598268/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12842755)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: The tyrosine kinase inhibitors (TKIs) asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib have been approved for chronic myelogenous leukemia (CML) therapy.</li>
<li>Risultato chiave: To better clarify TKIs&#x27; pulmonary risk, we used the European database EudraVigilance to conduct a study on adverse events suspected to be caused by the TKIs asciminib, bosutinib, dasatinib, imatinib, nilotinib, and ponatinib when used for CML therapy.</li>
<li>Rilevanza clinica: The results indicate that respiratory disorders induced by the TKIs dasatinib and bosutinib need to be diagnosed in a timely manner, and suggest that caution should be taken when prescribing these TKIs to patients affected by CML and pulmonary comorbidities.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): ICSRs reporting SARs that occurred following the prescription of dasatinib, imatinib, nilotinib, ponatinib, bosutinib, and asciminib from 1 January 2020 to 31 December 2024 were collected, analyzed, and compared.</li>
<li>Risultato principale (full text OA): Table 1 shows the total number of ICSRs, the number of serious and non-serious cases, and the serious/non-serious ratio of SAR signals related to dasatinib, asciminib, bosutinib, imatinib, nilotinib, and ponatinib prescription.</li>
<li>Dettaglio utile (full text OA): The results show RORs of 9.55 (95%; C.I.</li>
<li>Messaggio clinico (full text OA): The disproportionality analysis comparing the signals for PE and PAH associated with bosutinib and the data for these adverse reactions reported with the TKIs dasatinib, asciminib, imatinib, nilotinib, and ponatinib produced RORs of 2.32 (95%; C.I.</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>Dose strategy / consolidamento (2)</h3>
<p></p>
<p>#### Advances in Targeting BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt; Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.</p>
<ul>
<li>Impact score: 12 | Tipo: Review</li>
<li>PMID: 41599389 | 10.3390/molecules31020341</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41599389/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41599389/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12843680)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to imatinib remains a therapeutic challenge, largely driven by point mutations within the kinase domain of the &lt;i&gt;BCR-ABL&lt;/i&gt;, among which the &lt;i&gt;T315I&lt;/i&gt; substitution constitutes the most clinically significant barrier.</li>
<li>Risultato chiave: Recent advances highlight aminopyrimidine-derived scaffolds and their evolution into thienopyrimidines, oxadiazoles, and pyrazines with improved activity against &lt;i&gt;BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt;&lt;/i&gt;.</li>
<li>Rilevanza clinica: Hybrid molecules derived from approved &lt;i&gt;TKIs&lt;/i&gt;, including GNF-7, olverembatinib, and HG-7-85-01, exemplify rational design trends that balance efficacy with improved safety.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): In this review, we summarized the diverse medicinal chemistry strategies currently being pursued to overcome the BCR-ABLT315I gatekeeper mutation, one of the most challenging resistance mechanisms in chronic myeloid leukemia therapy.</li>
</ul>
<p></p>
<hr>
<p></p>
<p>#### Dual Proteasome and Histone Deacetylase Inhibition Overcomes Tyrosine Kinase Inhibitor Resistance in Breakpoint Cluster Region: Abelson 1-Driven Leukaemia Cell Lines.</p>
<ul>
<li>Impact score: 5 | Tipo: Preclinico / laboratorio</li>
<li>PMID: 41696976 | 10.1111/jcmm.71053</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41696976/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41696976/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12908417)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to tyrosine kinase inhibitors (TKIs) remains a major challenge in breakpoint cluster region (BCR)::Abelson 1 (ABL1)-driven leukaemias.</li>
<li>Risultato chiave: Viability, cytotoxicity, and caspase-3/7 activity were assessed following single-agent treatment with asciminib, ponatinib, bortezomib, or panobinostat.</li>
<li>Rilevanza clinica: Asciminib showed reduced potency in resistant models and a right-shifted dose-response curve in T315I cells, whereas ponatinib retained activity across BCR::ABL1 variants.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): For single‐agent dose–response experiments, cells were treated with 10‐fold serial dilutions ranging from 0 to 1 μM for asciminib and ponatinib and from 0 to 100 nM for bortezomib and panobinostat.</li>
<li>Risultato principale (full text OA): Asciminib is a STAMP inhibitor approved for CML [18].</li>
<li>Dettaglio utile (full text OA): (A) CML cell lines (K562, K562 PR, K562 IR, Ba/F3 asc‐R, Ba/F3 PR, Ba/F3 BCR::ABL, and Ba/F3 T315I) were exposed to asciminib (0–1 μM) for 72 h, and cell viability was measured using the Cell Counting Kit‐8 (CCK‐8) assay.</li>
<li>Messaggio clinico (full text OA): A prior clinical trial explored the combination of a proteasome inhibitor with an HDAC inhibitor in a phase I dose‐escalation study involving belinostat and bortezomib in adult patients with acute leukaemia, myelodysplastic syndromes, or blast‐crisis CML [27].</li>
</ul>
<p></p>
<hr>
<p></p>
<h3>Sintesi (review/linee guida) (1)</h3>
<p></p>
<p>#### Advances in Targeting BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt; Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules.</p>
<ul>
<li>Impact score: 12 | Tipo: Review</li>
<li>PMID: 41599389 | 10.3390/molecules31020341</li>
<li>Link PubMed: <a href="https://pubmed.ncbi.nlm.nih.gov/41599389/" target="_blank">https://pubmed.ncbi.nlm.nih.gov/41599389/</a></li>
<li>Open Access (Europe PMC/PMC): sì (PMC12843680)</li>
</ul>
<p></p>
<p><b>Mini-riassunto (da abstract, estrattivo):</b></p>
<ul>
<li>Tipo di studio/popolazione: Resistance to imatinib remains a therapeutic challenge, largely driven by point mutations within the kinase domain of the &lt;i&gt;BCR-ABL&lt;/i&gt;, among which the &lt;i&gt;T315I&lt;/i&gt; substitution constitutes the most clinically significant barrier.</li>
<li>Risultato chiave: Recent advances highlight aminopyrimidine-derived scaffolds and their evolution into thienopyrimidines, oxadiazoles, and pyrazines with improved activity against &lt;i&gt;BCR-ABL&lt;sup&gt;T315I&lt;/sup&gt;&lt;/i&gt;.</li>
<li>Rilevanza clinica: Hybrid molecules derived from approved &lt;i&gt;TKIs&lt;/i&gt;, including GNF-7, olverembatinib, and HG-7-85-01, exemplify rational design trends that balance efficacy with improved safety.</li>
</ul>
<p></p>
<p><b>Riassunto aggiuntivo (full text Open Access, estrattivo):</b></p>
<ul>
<li>Metodi (full text OA): non riportato.</li>
<li>Risultato principale (full text OA): non riportato.</li>
<li>Dettaglio utile (full text OA): non riportato.</li>
<li>Messaggio clinico (full text OA): In this review, we summarized the diverse medicinal chemistry strategies currently being pursued to overcome the BCR-ABLT315I gatekeeper mutation, one of the most challenging resistance mechanisms in chronic myeloid leukemia therapy.</li>
</ul>
<p></p>
<hr>
</body>
</html>
